Koichi Ohata
Overview
Explore the profile of Koichi Ohata including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
59
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fujii H, Makiyama A, Nishimura K, Iihara H, Hirose C, Ohata K, et al.
J Pharm Health Care Sci
. 2024 Jul;
10(1):36.
PMID: 38987837
Background: Anamorelin is expected to improve cancer cachexia by increasing lean body mass (LBM) due to increased appetite and protein synthesis. However, the effect of anamorelin on cancer cachexia in...
2.
Watanabe D, Fujii H, Ohata K, Iihara H, Makiyama A, Kobayashi R, et al.
BMC Cancer
. 2023 Nov;
23(1):1078.
PMID: 37940878
Background: Several studies have reported an association between severe neutropenia and long-term survival in patients treated with trifluridine-tipiracil (TAS-102). Because some of these studies failed to address immortality time bias,...
3.
Hishida-Sadaka S, Iihara H, Ohata K, Matsuoka S, Watanabe D, Iwashita T, et al.
Support Care Cancer
. 2023 Oct;
31(12):657.
PMID: 37884842
Purpose: Modified FOLFIRINOX (mFFX), a standard chemotherapy regimen for advanced pancreatic cancer (APC), is expected to be associated with a higher risk of chemotherapy-induced nausea and vomiting (CINV). Herein, we...
4.
Matsuoka S, Fujii H, Iihara H, Ohata K, Hirose C, Watanabe D, et al.
Anticancer Res
. 2023 Apr;
43(5):2351-2357.
PMID: 37097664
Background/aim: Although combination chemotherapy with trifluridine/tipiracil (TAS-102) and bevacizumab (BEV) is highly effective for metastatic unresectable colorectal cancer (mCRC), this combination chemotherapy often induces nausea and vomiting. To identify risk...
5.
Sadaka S, Iwashita T, Fujii H, Kato-Hayashi H, Ohata K, Uemura S, et al.
J Clin Med
. 2022 Oct;
11(19).
PMID: 36233762
Aims: To evaluate the impact of first-line mFFX-induced PN on the efficacy of second-line GnP in patients with APC. Methods: A database containing patients with APC was retrospectively analyzed to...
6.
Fujii H, Sadaka S, Ajisawa K, Okumura N, Makiyama A, Iihara H, et al.
Anticancer Res
. 2022 Aug;
42(9):4581-4588.
PMID: 36039452
Background/aim: Although peripheral neuropathy (PN) is a common adverse event in patients treated with oxaliplatin as first-line chemotherapy (1st-OX) for advanced gastric cancer, the effect of PN on the efficacy...
7.
Fujii H, Ueda Y, Hirose C, Ohata K, Sekiya K, Kitahora M, et al.
J Pharm Health Care Sci
. 2022 Mar;
8(1):8.
PMID: 35236407
Background: The effect of pharmaceutical intervention to treat adverse events on quality of life (QOL) in outpatients receiving cancer chemotherapy is unclear. We investigated whether pharmaceutical intervention provided by pharmacists...
8.
Fujii H, Koda M, Sadaka S, Ohata K, Kato-Hayashi H, Iihara H, et al.
J Pharm Health Care Sci
. 2021 Aug;
7(1):27.
PMID: 34334136
Background: Cancer chemotherapy usually improves clinical outcomes in patients with advanced pancreatic cancer (APC), but can also cause moderate-to-severe adverse events (AEs). We investigated the relationship between moderate-to-severe AEs and...
9.
Ohata K, Fujii H, Sadaka S, Kato-Hayashi H, Iihara H, Kobayashi R, et al.
Anticancer Res
. 2021 Jul;
41(7):3643-3648.
PMID: 34230162
Background/aim: To clarify the risk of chemotherapy-induced nausea and vomiting (CINV) with GnP therapy, gemcitabine (GEM) plus nab-paclitaxel (nab-PTX), we compared CINV between GEM and GnP therapy. Patients And Methods:...
10.
Kitagawa J, Kobayashi R, Nagata Y, Kasahara S, Ono T, Sawada M, et al.
Int J Cancer
. 2020 Sep;
148(6):1462-1469.
PMID: 32984946
Oral mucositis is a common and distressing complication in patients receiving high-dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT). We reported previously in a single-center retrospective analysis that zinc-L-carnosine...